On July 29, 2022 Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers, reported that it will release second quarter 2022 financial results Friday, August 5, 2022 (Press release, Forma Therapeutics, JUL 29, 2022, View Source [SID1234617146]). Forma management will host an investment community conference call at 8 a.m. Eastern Daylight Time (EDT) on August 5, 2022 to discuss these financial results and provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors may participate in the call by using the registration link here. Once registered, participants will receive a dial-in number as well as a PIN to enter the event. A live webcast of the conference call will be available in the "News & Investors" section of Forma’s website at www.formatherapeutics.com.